2026· ITM Web of Conferences· 0 citations· 38 references
TL;DR
This review explores current methods, technologies and governance structures for the sharing of genomic data, as well as national genome initiatives and the genomics industry to offer a broad overview and proposes four recommendations for future directions to improve the consistency, security and interoperability of data sharing from the genome.
Abstract
One of the difficulties of the widespread application of genomic medicine is the sharing of patient genomic data quickly and securely with other health care systems. This review explores current methods, technologies and governance structures for the sharing of genomic data, as well as national genome initiatives and the genomics industry to offer a broad overview. The aim is to determine the existing practice, to discuss important technical and regulatory issues and to present practical suggestions that can facilitate future development. The review is carried out using the methodology for scoping reviews developed by Arksey and O'Malley, and information from peer-reviewed literature, gray literature, national genomics programs and industry reports. Four research questions were posed: How does the sharing of genomic data occur in clinical practice, in research settings, in national genomic programs and in commercial genomics companies? 37 relevant studies were identified and analyzed, and seven key components for effective genomic data-sharing systems were identified. These studies included clinical implementation models, research models, as well as considering ethical, legal or policy issues. Given the results, there are several technologies and frameworks to share clinical genomic data, however, there is not as wide-spread a large scale implementation as desired. Scalable infrastructures, inequities in clinical/academic genomic systems and different degrees of genomic medicine uptake in health services are key challenges. The review proposes four recommendations for future directions to improve the consistency, security and interoperability of data sharing from the genome and to promote greater uptake of the use of the clinical genome and innovation in precision medicine.
ABSTRACT Introduction The translational nature of genomics highlights the importance of developing a robust genomic data governance framework. To inform the development of such a framework for Australia, we conducted a scoping review to identify genomic data governance and management differences between research and cl...
Alice M. Kim, Bronwen Merner, Mark Taylor et al.· Health Expectations· 0 citations
Next-generation sequencing has transformed diagnosis, prognosis, and treatment across rare disease, cancer, immunology, and infectious disease. As variant interpretation may evolve with emerging evidence, sharing genetic data is essential to improve diagnostic accuracy and advance genomic medicine. However, practical g...
J. Lerner-Ellis, Y. Fisher, Ma'n H. Zawati et al.· American Journal of Human Ge...· 0 citations
INTRODUCTION
As precision medicine increasingly relies on genetic information, the development of reliable genomic point-of-care tests (POCTs) is essential. However, the number of technologies that have reached true clinical usability is limited. There is a growing need for POCTs that enable rapid, accurate analysis of...
S. Haston, J. Elgey, O. Ewedairo et al.· Pharmacogenomics (London)· 0 citations
Simple Summary Cancer diagnosis increasingly relies on molecular tests performed on stored blood and tissue samples, and the reliability of those tests depends on how carefully the samples were collected, processed, and stored. Biobanks are the facilities that safeguard these samples, and international guidelines defin...
Andreea-Adriana Neamțu, Robert Barna, Alon Vigdorovits et al.· Cancers· 0 citations
A precision medicine strategy is likely to be more impactful, when pharmacogenomics (PGx) guided selection of drugs and dosage wherever applicable is implemented across the globe. In regions where resources are disproportionately distributed, PGx implementation in routine clinical care can play a critical role in ensur...
Mohamad Nagy, G. M. Raj, R. Priyadarshini et al.· Pharmacogenomics (London)· 0 citations
A framework for evaluating the translational impact of the Gabriella Miller Kids First Program enables systematic assessment of how research investments contribute to clinically actionable knowledge and translational impact, providing a model for evaluating future precision medicine and pediatric oncology research init...
Vanessa I. Barnes· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.